I am a
Home I AM A Search Login

Papers of the Week

2022 Dec 17

J Eur Acad Dermatol Venereol

Spesolimab improves patient-reported outcomes in patients with generalized pustular psoriasis: results from the Effisayil 1 study.


Navarini AA, Prinz JC, Morita A, Tsai T-F, Viguier M-A, Li L, Thoma C, Sivalingam M, Lebwohl MG
J Eur Acad Dermatol Venereol. 2022 Dec 17.
PMID: 36527385.


Generalized pustular psoriasis (GPP) is a rare inflammatory skin disease with a considerable clinical burden. In the Effisayil 1 study, spesolimab, an anti-interleukin-36 receptor monoclonal antibody, demonstrated efficacy in treating GPP flares.